Deep vein thrombosis screening: Difference between revisions
Jump to navigation
Jump to search
(New page: ==Value of screening== There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains * The strongest risk factor ...) |
No edit summary |
||
| Line 2: | Line 2: | ||
There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains | There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains | ||
* The strongest risk factor for VTE recurrence is the prior VTE event itself. | * The strongest risk factor for VTE recurrence is the prior VTE event itself. | ||
* In VTE patients where the cause was unknown, after discontinuation of warfarin irrespective of the presence of inherited thrombophilia, are at high risk of recurrence, | |||
Revision as of 14:27, 24 August 2011
Value of screening
There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains
- The strongest risk factor for VTE recurrence is the prior VTE event itself.
- In VTE patients where the cause was unknown, after discontinuation of warfarin irrespective of the presence of inherited thrombophilia, are at high risk of recurrence,